Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 17/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334242 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2ITGA4ITGB1MEN1ALDH1A1 | |
| SCHEMBL13923528 | 0.82 | SLC6A4 (0.53) | SMN1; SMN2ITGA4ITGB1 | |
| SCHEMBL3925001 | 0.80 | LTA4H (0.61) | SMN1; SMN2 | |
| SCHEMBL6285380 | 0.80 | LTA4H (0.61) | SMN1; SMN2 | |
| SCHEMBL6285385 | 0.80 | LTA4H (0.61) | SMN1; SMN2 | |
| SCHEMBL5719872 | 0.80 | ITGA4 (0.50) | SMN1; SMN2ITGA4ITGB1MEN1ALDH1A1 | |
| SCHEMBL1312190 | 0.80 | ITGA4 (0.55) | ITGA4ITGB1 | |
| SCHEMBL5719875 | 0.80 | ITGA4 (0.50) | SMN1; SMN2ITGA4ITGB1MEN1ALDH1A1 | |
| SCHEMBL1312192 | 0.80 | ITGA4 (0.55) | ITGA4ITGB1 | |
| SCHEMBL14037387 | 0.80 | ITGA4 (0.55) | ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144678-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008124756-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-0094233-B1 | IMMUNE MODULATOR PEPTIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144678-A1 | COMPOSITIONS AND METHODS FOR TREATING BONE CANCER | BDKRB1, BDKRB2, HPGDS | SMN1; SMN2 4671/4885ITGA4 2484/4885ITGB1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.